Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients With Locally Recurrent or Metastatic Breast Cancer

Global EMBRACE Study Compared Eribulin to Treatment of Physician's Choice

CHICAGO, June 6, 2010 – Results of a Phase III study presented today at the American
Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's
eribulin mesylate significantly improved median overall survival (OS)
compared with Treatment of Physician's Choice (TPC) in heavily pre-treated
metastatic breast cancer patients.[1]
[...]